UCB SA operates as a specialized biopharmaceutical company with a primary focus on two main therapeutic areas: neurology (central nervous system) and immunology. The company's business model is centered around the research, development, and commercialization of prescription drugs for severe diseases with high unmet medical needs. Key revenue-generating products include Cimzia (for immunology), Vimpat, Briviact, and Keppra (for epilepsy), Neupro (for Parkinson's disease), and newer growth drivers like Bimzelx (for psoriasis) and Evenity (for osteoporosis). UCB generates revenue primarily through the direct sale of these branded therapeutics to hospitals, pharmacies, and healthcare systems globally. The company has a significant geographic footprint, operating in approximately 40 countries, with major markets in the United States, Europe, and Japan. UCB's competitive position is bolstered by its robust pipeline of biologics and small molecules, significant investments in research and development, and strategic acquisitions to expand its capabilities in rare diseases. By concentrating on specialized, high-need disease areas rather than broad consumer healthcare, UCB maintains strong pricing power and patent protection for its core portfolio.
